Award Number: DAMD17-02-1-0416

TITLE: Novel Targets for the Diagnosis and Treatment of Breast Cancer Identified by Genomic Analysis

PRINCIPAL INVESTIGATOR: Carol A. Westbrook M.D., Ph.D.

CONTRACTING ORGANIZATION: Boston Medical Center Corporation
                        Boston MA 02118-2304

REPORT DATE: December 2006

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
                  Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                        Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Novel Targets for the Diagnosis and Treatment of Breast Cancer Identified by Genomic Analysis

Chromosomal rearrangements which result in localized increases of genetic material are frequent in breast cancer, and occur consistently in certain genomic regions. The resulting increase in expression of genes contained within these amplifications contributes to the malignant phenotype. Such amplified genes, such as Her2-Neu, provide targets for diagnosis and for the development of inhibitory drugs. The purpose of this study is to use novel genomic technologies to find new genes in breast cancer that are both highly amplified and are suitable targets by virtue of the fact that they are membrane-associated (receptors, membrane antigens, secretory proteins). The aims of the study are (1) To specify intervals of genomic amplification (amplicons) in primary breast cancer cell lines using genomic microarrays; (2) To prepare a database of membrane-associated genes, selected by differential hybridization of RNA prepared from fractionated microsomes; (3) To use the database to select membrane-associated genes that are located within amplicons, and measure their expression in the primary cell line using cDNA arrays, in order to select those that are upregulated. These genes will provide new insights and reagents for diagnosis and treatment of breast cancer.
# Table of Contents

- **Introduction** ........................................................................................................... 4  
- **Body** ..................................................................................................................... 5  
- **Key Research Accomplishments** ........................................................................ 8  
- **Reportable Outcomes** ......................................................................................... 8  
- **Conclusions** ........................................................................................................ 9  
- **References** ......................................................................................................... 10  
- **Appendices and supporting documents** ............................................................ 11
INTRODUCTION
“Novel Targets for the Diagnosis and Treatment of Breast Cancer”

Chromosomal amplifications contain multiple copies of a genome segment. Regions that are consistently found to be amplified in breast cancer contain “driver” genes whose increased expression provides a selective advantage the cell, and may also provide targets for diagnosis and treatment. HER-2Neu is one successful example. There is a great interest in identifying other such genes, particularly those that might prove useful for treatment or diagnosis. Among this category of genes, the most clinically-useful are those that are membrane-associated, such as receptors, transmembrane genes, or secreted proteins. We proposed to use genomic methods to identify genes within amplicons that are also membrane-associated.

We proposed to identify these genes using a novel screening method, which takes advantage of the fact that proteins which function at the membrane surface are preferentially translated from membrane-associated ribosomes, and their RNA will give a differential signal on cDNA expression arrays. We can then select the genes and ESTs from among them that are contained within amplicons, providing we have accurate sequence localizations for both the EST and the amplicon. We further refined our objectives since the submission of this proposal to target our efforts toward pleural metastatic disease.

Malignant pleural effusions represent a significant problem in the management of patients with breast cancer. Approximately half of patients with disseminated disease will develop pleural effusions and many of these patients will have respiratory problems or other symptoms requiring intervention [1]. These patients tend to have a poor prognosis [1], although it is not clear if this is due to the pleural metastases or their advanced breast disease. Although pleural disease occurs frequently in advanced stage disease, it is not inevitable, suggesting that there are tumor-specific features which regulate the ability to proliferate in the pleural space. Understanding the basis of this tissue tropism might provide some ideas in identifying therapeutic targets for controlling this growth. To identify factors which are associated with pleural metastases, we compared cell lines derived from primary breast tumors to pleural metastases, examining DNA copy number of gene expression levels. We further refined our database to select amplified and over-expressed genes that are membrane-associated.

Our specific aims are:
1. To use genomic array analysis to identify and delineate amplicons in breast cancer, comparing primary to pleural metastatic disease.
2. To identify genes within these amplicons that encode surface-expressed molecules, using cDNA array hybridization of fractionated polysomes.
3. To measure the expression levels of these selected genes, identifying those that are the upregulated targets of amplification in pleural metastatic disease.

We hope to identify a set of novel genes that are overexpressed in breast cancer with translational significance, as they represent potential targets for antibodies (surface antigens), receptors for external factors that regulate cell growth, or circulating tumor markers (secreted peptides). Identifying these driver genes will provide new insights and reagents for diagnosis and treatment of breast cancer.
Task 1. To specify intervals of genomic amplification in breast cancer cell lines or explants using genomic microarrays.

Task 2: To prepare a database containing at most 9,000 to 15,000 genes expressed in the MCF7 breast cancer cell line that are likely to be membrane-associated.

Task 3. To select genes within amplicons and measure their expression level, to identify those that are upregulated.

The work comprised two major projects. The first was the preparation of the database of membrane associated-genes in breast cancer (Task 2) and the second involved analysis of pleural mets vs. primary breast cancer, to identify amplicons and highly expressed genes, and to correlate with the membrane database, Tasks 1 and 3.

I. Preparation of the database of surface-expressed molecules.

This was reported previously, and has been published in Cancer Research.


A copy of the manuscript is included in the appendix.

II. Amplicons and gene expression in pleural metastatic disease.

Materials and Methods

All cell lines had been developed from patient specimens of infiltrating ductal carcinoma collected at the University of Illinois at Chicago Cancer Center as previously described [2]. The tissue was taken from a resected breast primary (for the primary cell line group) or pleural fluid in patients with pleural metastases (for the metastatic cell line group). Each cell line was cultured following standard cell culture protocols, and was expanded to $1 \times 10^7$ before harvesting.

**RNA extraction and profiling on Affymetrix arrays**

Total RNA was extracted from each sample using TRIzol reagent (Invitrogen, Carlsbad, CA) following the recommended manufacturer’s protocol. RNA was quantified by UV spectrophotometry and the quality was checked by ensuring the ratio of absorbance at 260/280 nm ≥ 1.8 as well as verifying the presence of ribosomal bands via gel electrophoresis. 20 μg of total RNA for each cell line was biotin labeled in two separate and equal reactions according to the recommended Affymetrix protocol. Each reaction (2 separate labeling reactions per cell line) was hybridized to Affymetrix U133A oligonucleotide microarrays according to the manufacturer’s recommended protocol. The microarrays were washed and scanned according to standard protocol, and the resulting CEL files were processed as follows.

**Gene expression calculation and processing**
The CEL files for each of the microarray hybridizations (14 total = 3 metastatic cell lines and 4 primary cell lines all hybridized in duplicate) were processed using the Bioconductor software suite (a set of R [3] libraries available at http://www.bioconductor.org). The Robust Multiarray Average (RMA) algorithm from Bioconductor [4-6] was used for normalization, background calculation and subtraction, and expression value calculation.

**DNA copy number analysis**

DNA was extracted from 1x10⁷ cells previously flash frozen in liquid nitrogen using the Puregene DNA isolation kit (Gentra, Minneapolis, MN). DNA amplification analysis was performed using the GenoSensor Array 300 system (Vysis, Downers Grove, IL) as follows. 1µg each of sample DNA and reference DNA (female DNA obtained from Stratagene, La Jolla, CA) was labeled with Cy-3 and Cy-5 fluorophores, respectively. These labeled products were hybridized to the GenoSensor Array 300 for 72 hours according to the manufacturer’s specifications. Following the recommended washing procedure, the slides were scanned using the GenoSensor Reader System. Using the manufacturer’s software, the relative DNA amplification for each probe was calculated along with a *p*-value indicating the statistical significance. A *p*-value of ≤ 0.01 was considered significant.

**Statistical calculations**

To determine which genes were likely to be associated with the pleural metastatic phenotype, we applied statistical and differential expression filtering methods to exclude genes from the total expression group that were not likely to correlate with the phenotype or were not expressed strongly enough. First, *t*-tests with equal variance were performed for each microarray element, calculating the probability of differential expression between the primary and metastatic group. The probability was calculated directly from the *t* distribution with 12 (6 metastatic + 8 primary - 2) degrees of freedom. We used the Benjamini and Hochberg [7] method of controlling the False Discovery Rate (FDR) for multiple hypothesis testing correction. The adjusted threshold _ was set at 0.05. To ensure each gene was expressed at a high enough level, we filtered out genes with less than 2-fold differential expression between the primary and metastatic groups. To determine the top correlated genes, Pearson’s correlation was calculated for each gene with a vector of idealized phenotypes (i.e. [1,1,1,…,-1,-1,-1]). For clustering, complete linkage was used with (1 – Pearson’s correlation) as a distance metric.

**Results**

**Gene expression signature of pleural metastases**

To investigate the gene expression signature of pleural metastases, we elected to use cell lines that had been created from either pleural metastases or primary breast tumors. Seven cell lines were available for our analysis; three derived from pleural metastases and four derived from primary tumors. We hybridized RNA from these cell lines to Affymetrix U133A microarrays and calculated expression values for 22,283 genetic elements. The global gene expression profiles from the two groups were compared, and after applying the statistical and expression filtering as described above, 107 genes (represented by 121 probe sets) were found to show differential expression between the two groups. We define this as the gene expression signature of pleural metastases. Of these 107 genes, 65 were upregulated in pleural metastatic disease, and 42 genes were downregulated. Strong intra-group clustering was found using these 121 probe sets (Figure 1). Correlation with the metastatic phenotype
was calculated for each gene, and the top 18 genes were selected for further analysis (these are listed in Table 1). A plot of the expression levels of the top correlated genes is seen in Figure 2.

**A unique metastatic profile**

To investigate the possibility that common metastatic genes were driving these pleural metastases, we compared our pleural metastatic profile with two recently reported signatures. A 70-gene expression signature has been reported to be highly correlated with metastasis and poor-prognosis [8]. We compared our pleural metastatic profile with the 70-gene expression signature to determine if any of the poor-prognosis genes were present in our profile. Of the 70-genes, we found 52 to be represented by elements on the Affymetrix U133A GeneChip. Of these 52, only two were found in our pleural metastatic profile: maternal embryonic leucine zipper kinase (MELK) and nucleolar and spindle associated protein 1 (NUSAP1). Interestingly, while both were upregulated in the poor-prognosis profile, they were both found downregulated in pleural metastatic disease.

We also compared our pleural metastatic profile with a recently reported 102-gene profile specific for breast cancer metastases in bone [9]. Given that the 102-gene profile was performed on Affymetrix U133A GeneChips, we were able to directly compare the results. Only one gene, tumor necrosis factor alpha-induced protein 2 (TNFAIP2) was found in common with these two datasets. While downregulated 2.2 fold in bone metastases, it was found to be 2.1 fold upregulated in pleural metastases.

**Genes highly correlated with pleural metastases**

To select those genes whose expression is highly correlated with the pleural metastatic phenotype, we calculated Pearson’s correlation with an idealized phenotypic vector (i.e. [1,1,1,…,-1,-1,-1]) for each gene as described above. Genes with a correlation coefficient above an arbitrarily chosen cutoff of 0.85 were selected for further analysis. Those 18 genes are listed in Table 1, and a clustering based on their expression levels is shown in Figure 2.

To investigate the potential role of the genes that were most highly correlated with the pleural metastatic phenotype we correlated each Affymetrix probe set with one or more Gene Ontology[10] Biochemical Process (BP) annotations. One third of the genes (6 of 18) have no BP annotation, while another third appear to be involved in metabolism (4 of 18) or cell growth and maintenance (2 of 18). The remaining probe sets with BP annotation are split between transcription and translation, angiogenesis, and protein phosphorylation.

**A potential role of gene amplification**

Increased DNA copy number has recently been shown to play a driving role in increased levels of gene expression [11, 12]. To explore the possibility that gene upregulation in the pleural signature might be associated with genomic amplification, DNA copy number analysis was performed using competitive DNA hybridization on glass slides. The Vysis chip contains 287 targets spotted in triplicate which represent genetic segments that are frequent sites of genomic amplification and genomic loss. Fluorescently labeled DNA from each of the seven cell lines was hybridized to the chip in competition with fluorescently labeled normal female DNA and scored for sites in which there was a statistically significant gain or loss.
The results of this study are shown in Figure 3, which displays both amplified and deleted chromosomal regions, comparing pleural to primary cell lines. While certain trends are evident, after applying the Benjamini Hochberg method of correcting for multiple hypothesis testing, there were no statistically significant amplifications that distinguished the metastatic group from the primary group. Despite this, several of the genes in our pleural metastatic signature fall in regions found to be amplified in one or more metastatic lines at a statistically significant level for that cell line, as summarized in Table 2. Of note, four genes in the pleural metastatic signature (two of which are included in the top correlated genes) are found in 10p11-15, a region which appears to be highly amplified in one of the metastatic lines (BCA-1) and moderately amplified in another metastatic line (BCA-4). 10p11-15 shows no amplification in the primary lines.

KEY RESEARCH ACCOMPLISHMENTS

> Preparation of database of membrane-associated and secreted genes in breast cancer
> Describing a gene expression signature that is highly correlated with metastatic disease
> Describing a set of genes that is amplified in pleural metastatic disease

REPORTABLE OUTCOMES

Manuscripts:

Abstracts:

CONCLUSIONS

The purpose of this study was to identify potential targets for the diagnosis and treatment of pleural metastatic breast cancer. We chose to use cell lines derived from patient tumors in order to have a model in which our findings can be tested. Furthermore, these are early-passage cultures, and as such are thought to be genetically similar to the tissue from which they were derived, with little cell-culture artifact.

Although the sample size was small, several interesting observations can be made. First, we identified a genetic signature that is associated with pleural metastatic disease. There is some evidence that this program may be unique to pleural metastases as it is independent from a signature shown to predict aggressive metastatic behavior and poor prognosis[8], as well as a signature of bony metastasis using a murine explant system[9]. The genes we identified as a genetic signature of pleural metastasis might be mediators of pleural tropism in breast cancer. Interestingly, of the 18 genes most highly correlated with pleural metastasis, half are involved with cellular metabolism or growth and maintenance, and might point to the biochemical modifications necessary for specialized growth of cells in the pleural cavity. Such pathways might be good targets for inhibitory drugs that might control tumor growth in the pleural space rather than a systemic impact.

The role of DNA amplification was examined to investigate the possibility that this mechanism is involved with the gene expression changes observed in the pleural metastatic cell lines. While there were no statistically significant changes observed between the metastatic and primary groups, there was an amplified region present in two out of three pleural metastatic cell lines that contained two of the top 18 genes most correlated with the metastatic phenotype and an additional two from the larger gene expression signature. While preliminary, this warrants further study to determine if this amplicon is driving this gene expression change in the metastatic lines.

The pleural space represents a good site for drug delivery and patients would benefit if their malignant pleural disease was controlled. In order to develop new therapies for the treatment of pleural effusions from the breast one needs to determine if the pleural disease is similar or dissimilar from primary breast tumors. While this study is limited by the number of cell lines available for analysis, it supports the theory that pleural metastatic disease represents a genetically distinct form of breast cancer with highly correlated genes suitable for further analysis as therapeutic targets.
REFERENCES


APPENDICES

Reprint attached for the following manuscript:


SUPPORTING DOCUMENTS

Table 1  **Genes most correlated with the pleural metastatic phenotype.**

Table 2  **Genes from the pleural metastatic profile found in amplified regions in pleural metastatic cell lines.** DNA copy number is listed for each cell line for the given genes from the pleural metastatic profile. Amplifications considered statistically significant are shaded gray. (Specific DNA copy number for DNAJC1 is unavailable due to lack of genomic probe at that location, however it is within the amplified region in the pleural metastatic cell lines.)

Figure 1. **Hierarchical clustering diagram.** The expression of our 121 probe set profile was used to cluster the 14 cell lines. (1 – the pearson correlation) was used as a distance metric and complete linkage was used for joining nodes. The data is displayed such that each row represents one probe set and each column represents one cell line hybridization. Sample names are below each column; “a” and “b” refer to duplicate hybridizations. The black and yellow bars represent pleural metastatic and primary cell lines, respectively. Above the columns and to the left of the rows are the hierarchical dendrograms for their respective dimension.

Figure 2. **Expression of genes most correlated with pleural metastatic phenotype.**

Figure 3. **Percentage of cell lines sharing a relative DNA copy gain or loss for primary and pleural metastatic groups.** Statistically significant gains and losses are plotted in green and red, respectively. Probes are plotted according to their genomic position on each chromosome. Centromeres are represented by dashed lines.
<table>
<thead>
<tr>
<th>LocusLink</th>
<th>Affymetrix ID</th>
<th>Gene Name</th>
<th>Description</th>
<th>Chromosomal Band</th>
<th>MET/PRI Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>64215</td>
<td>218409_s_at</td>
<td>DNAJC1</td>
<td>DnaJ (Hsp40) homolog, subfamily C, member 1</td>
<td>10p12.33-p12.32</td>
<td>3.29</td>
</tr>
<tr>
<td>9236</td>
<td>214151_s_at</td>
<td>CPR8</td>
<td>cell cycle progression 8 protein</td>
<td>15q21.1</td>
<td>3.11</td>
</tr>
<tr>
<td>27236</td>
<td>218230_at</td>
<td>ARFIP1</td>
<td>ADP-ribosylation factor interacting protein 1 (arfaptin 1)</td>
<td>4q31.3</td>
<td>3.06</td>
</tr>
<tr>
<td>9236</td>
<td>221511_x_at</td>
<td>CPR8</td>
<td>cell cycle progression 8 protein</td>
<td>15q21.1</td>
<td>2.93</td>
</tr>
<tr>
<td>NA</td>
<td>AFFX-r2-Hs28SrRNA-3_at</td>
<td>28S rRNA</td>
<td>28S ribosomal RNA</td>
<td></td>
<td>2.89</td>
</tr>
<tr>
<td>22944</td>
<td>205664_at</td>
<td>KIN</td>
<td>KIN, antigenic determinant of recA protein homolog (mouse)</td>
<td>10p15-p14</td>
<td>2.60</td>
</tr>
<tr>
<td>8976</td>
<td>205809_s_at</td>
<td>WASL</td>
<td>Wiskott-Aldrich syndrome-like</td>
<td>7q31.3</td>
<td>2.33</td>
</tr>
<tr>
<td>22836</td>
<td>216048_s_at</td>
<td>RHOBTB3</td>
<td>Rho-related BTB domain containing 3</td>
<td>5q15</td>
<td>2.24</td>
</tr>
<tr>
<td>3419</td>
<td>202069_s_at</td>
<td>IDH3A</td>
<td>isocitrate dehydrogenase 3 (NAD+) alpha</td>
<td>15q25.1-q25.2</td>
<td>2.21</td>
</tr>
<tr>
<td>7466</td>
<td>202908_at</td>
<td>WFS1</td>
<td>Wolfram syndrome 1 (wolframin)</td>
<td>4p16</td>
<td>2.19</td>
</tr>
<tr>
<td>64400</td>
<td>218373_at</td>
<td>FTS</td>
<td>fused toes homolog (mouse)</td>
<td>16q12.2</td>
<td>2.16</td>
</tr>
<tr>
<td>140894</td>
<td>209422_at</td>
<td>C20orf152</td>
<td>chromosome 20 open reading frame 152</td>
<td>20q11.23</td>
<td>2.11</td>
</tr>
<tr>
<td>7127</td>
<td>202510_s_at</td>
<td>TNFAIP2</td>
<td>tumor necrosis factor, alpha-induced protein 2</td>
<td>14q32</td>
<td>2.06</td>
</tr>
<tr>
<td>NA</td>
<td>AFFX-M27830_5_at</td>
<td>28S rRNA</td>
<td>28S ribosomal RNA</td>
<td></td>
<td>2.04</td>
</tr>
<tr>
<td>3837</td>
<td>213803_at</td>
<td>KPNB1</td>
<td>karyopherin (importin) beta 1</td>
<td>17q21.32</td>
<td>0.43</td>
</tr>
<tr>
<td>2318</td>
<td>207876_s_at</td>
<td>FLNC</td>
<td>filamin C, gamma (actin binding protein 280)</td>
<td>7q32-q35</td>
<td>0.42</td>
</tr>
<tr>
<td>3837</td>
<td>213574_s_at</td>
<td>KPNB1</td>
<td>karyopherin (importin) beta 1</td>
<td>17q21.32</td>
<td>0.37</td>
</tr>
<tr>
<td>9833</td>
<td>204825_at</td>
<td>MELK</td>
<td>maternal embryonic leucine</td>
<td>9p13.1</td>
<td>0.35</td>
</tr>
</tbody>
</table>
Table 2

<table>
<thead>
<tr>
<th>Affymetrix ID</th>
<th>Gene Name</th>
<th>Name</th>
<th>Chromosomal Band</th>
<th>Pleural metastatic cell lines</th>
<th>Primary cell lines</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BCA1</td>
<td>BCA2</td>
</tr>
<tr>
<td>212339_at</td>
<td>EPB41L1</td>
<td>erythrocyte membrane protein band 4.1-like 1</td>
<td>20q11.2-q12</td>
<td>1.42</td>
<td>1.02</td>
</tr>
<tr>
<td>217875_s_at</td>
<td>TMEPAI</td>
<td>transmembrane, prostate androgen induced RNA</td>
<td>20q13.31-q13.33</td>
<td>1.49</td>
<td>1.06</td>
</tr>
<tr>
<td>202265_at</td>
<td>BMI1</td>
<td>B lymphoma Mo-MLV insertion region (mouse)</td>
<td>10p11.23</td>
<td>2.14</td>
<td>0.93</td>
</tr>
<tr>
<td>203335_at</td>
<td>PHYH</td>
<td>phytanoyl-CoA hydroxylase (Refsum disease)</td>
<td>10pter-p11.2</td>
<td>2.68</td>
<td>0.97</td>
</tr>
<tr>
<td>205664_at</td>
<td>KIN</td>
<td>KIN, antigenic determinant of recA protein homolog (mouse)</td>
<td>10p15-p14</td>
<td>2.24</td>
<td>1.09</td>
</tr>
<tr>
<td>218409_s_at</td>
<td>DNAJC1</td>
<td>DnaJ (Hsp40) homolog, subfamily C, member 1</td>
<td>10p12.33-p12.32</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Figure 1.
Figure 2.
Figure 3
MATERIALS AND METHODS

Cell Line Preparation

MCF-7 cells were purchased from the American Type Culture Collection (Manassas, VA) and were cultured in Eagle’s MEM supplemented with 0.01 mg/mL bovine insulin, 10% fetal bovine serum in 5% CO₂ at 37°C.

Polysome Fractionation

Polysomes were fractionated by sucrose density gradient centrifugation with a modification of the method described by Mechler (4). After treatment with cyclohexamide (10 µg/mL) for 10 minutes at 37°C, 3 × 10⁶ MCF-7 cells in log growth were collected by scraping the dishes into cold PBS. The cells were then resuspended at a concentration of 2.5×10⁹ cells/mL in a hypotonic lysis buffer [10 mmol/L KCl, 1.5 mmol/L MgCl₂, and 10 mmol/L Tris-Cl (pH 7.4)] and were allowed to rest on ice for 10 minutes. After lysing cells with a Dounce homogenizer, nuclear and cell debris were removed by centrifugation at 2,000 × g for 20 minutes. The supernatant was loaded on a discontinuous-step sucrose gradient (2.5 mol/L, 2.1 mol/L, 1.95 mol/L, and 1.3 mol/L sucrose) and centrifuged at 26,000 × g for 5 hours. After centrifugation, successive 1.5 mL fractions were collected from the bottom of the centrifugation tube, and the A₅₉₀nm was measured to estimate the RNA content.

RNA Preparation

Total RNA was isolated from the pooled sucrose gradient fractions by mixing with TRIzol LS reagent (Invitrogen, Carlsbad, CA) at a 3:1 ratio.
MEMBRANE-ASSOCIATED AND SECRETED GENES IN BREAST CANCER

(3 parts TRIzol to 1 part sucrose), and extracting was done according to manufacturer’s instructions, followed by two additional salt precipitations [0.3 mol/L sodium acetate (pH 5.2) with 3 volumes of EtOH].

Real-time Quantitative Reverse-transcriptase PCR

First-Strand cDNA Synthesis. For generation of first-strand cDNA, ~1 µg of RNA was reverse-transcribed with Superscript II Reverse Transcriptase Kit (Invitrogen) in the presence of oligodeoxynucleotidic acid (12–18) in a final 20-µL reaction volume with reverse transcriptase per manufacturer’s recommended protocol followed by RNAse H treatment.

Real-time Reverse Transcriptase PCR Setup. Real-time PCR reactions were done with DNase-free cDNA templates generated above and SYBR Green PCR Core Reagents (Applied Biosystems, Branchburg, NJ) following manufacturer’s protocol with the following modifications: a 25 µL reaction was used, which contained 1× SYBR Green PCR mix, 3 mmol/L MgCl2, 1× deoxyxoy nucleotide triphosphate blend (0.2 mmol/L of dATP, dCTP, dGTP, and 0.4 mmol/L of dUTP), 0.625 units of AmpliTaq Gold, 0.125 units of AmpErase UNG, 50 mmol/L each of forward and reverse primer, and 1 µL of cDNA template. Default PCR amplification cycles were used as specified by the ABI Prism 7700 Sequence Detection System (Applied Biosystems): 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 15 seconds at 95°C, and 60°C for 1 minute. PCR amplification was followed by melting curve analysis with the following 3 hold cycles: 95°C for 15 seconds, 60°C for 20 seconds, and 95°C for 15 seconds, with the ramping time at maximum value 19:59 minutes at the last hold cycle. PCR amplification analysis was done on Sequence Detector v.1.7a, and melting curves were analyzed on Dissociation Curves v.1 according to Applied Biosystems guidelines.

MCF-7 cDNA template was used to generate a relative standard curve for either the endogenous control or the target gene. MCF-7 cDNA was serially diluted at 1:10 dilution factors starting with the highest arbitrary concentration of 50 ng/µL (taken from one twentieth of a reverse transcriptase reaction of 1 µg of starting total RNA). The sample templates were diluted at 1:5. All samples were done in triplicate. The sequence of the primers used in real time reverse transcriptase-PCR is as follows: endogenous control 18S rRNA: F: 5’-GTAACCGGTTGAAACCCAT-3’, R: 5’-CCATCCATCGGTAGTAGCG-3’ (6) with the expected size of 150 bp; and junctional adhesion molecule (JAM1): F: 5’-ACCTTGTGCTTATTGTTGC-3’, R: 5’-TGACCTTGACTGATGGCCTC-3’ with the expected size of 115 bp. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were obtained from Applied Biosystems (Foster City, CA). The quantity of target RNA (either JAM1 or GAPDH) was calculated by interpolating from the standard curve generated for that specific target. Both JAM1 and GAPDH quantities were normalized to 18S rRNA to calculate the relative quantity.

Microarray Hybridization and Data Processing

To minimize the effects of technical variability, membrane-associated and secreted and cytoplasmic RNA pools from one fractionation were processed in triplicate as follows. In three parallel reactions, 10 µg of total RNA from each pool was labeled, hybridized to the Affymetrix U133A microarray, processed, and scanned according to standard Affymetrix protocols. The six resulting membrane-associated and secreted and cytoplasmic RNA pools from one fractionation were processed in triplicate as follows. In three parallel reactions, 10 µg of total RNA from each pool was labeled, hybridized to the Affymetrix U133A microarray, processed, and scanned according to standard Affymetrix protocols. The six resulting

Membrane and Cytoplasmic Gene Reference Set

A reference set was developed containing genes that have to either membrane or cytoplasmic location and are represented on the Affymetrix U133A microarray with an automatic database search based on Swiss-Prot (11) release 44. Each Affymetrix microarray element has a unique Affymetrix Probe ID that can be mapped to at least one Swiss-Prot accession number.4 Each Swiss-Prot entry was then searched for “cellular location” comment tags. Proteins were considered to have membrane-associated and secreted localization if the Swiss-Prot cellular location tag contained one of the following identifiers: “secreted,” “Golgi,” “vesicular,” “membrane,” “lysosome,” or “peroxisome.” Entries were considered tentative if they contained “probable,” “possible,” “potential,” and “by similarity” and considered unambiguous if not. Entries that contained “nuclear,” “nucleus,” and “mitochondrial” were removed as there is some evidence that nuclear and mitochondrial proteins can be synthesized in either pathway (12, 13). This resulting list was then hand edited to remove entries containing multiple isoforms targeted for different subcellular compartments. Proteins are considered to have cytoplasmic localization if the Swiss-Prot cellular location tag contained “cytoplasmic” or “cytoplasm.” Again, entries with probable, possible, potential, and by similarity were considered tentative, and entries containing nuclear, nucleolus, and mitochondrial were removed. This list was hand edited to remove any entries with multiple isoforms as well as entries that contained any references to membrane association or organelles.

Statistical Calculations

At a given membrane-associated and secreted/cytoplasmic expression ratio r, the probability of belonging to the membrane-associated and secreted class for probe sets with ratios above r [p(m|r > r)] is calculated by using Bayes’ rule as shown in Equation 1.

\[
p(m|r > r) = \frac{p(r > r|m)p_m}{p(r > r|m)p_m + p(r > r|c)p_c} \tag{1}\]

where \(p(r > r|a)\) is the proportion of class a above ratio r. We calculate this probability for the entire range of membrane-associated and secreted/cytoplasmic ratios at intervals of 0.01 and choose the ratio that corresponds to the maximum ratio (we choose the lowest ratio for which the posterior probability rises to within 10% of the maximum probability). The \(P_c\) factor corresponds to the prior probability of belonging to class a.

Because of a lack of previous data on which to base our prior probabilities, we estimate these prior probabilities by determining the contributions of the two known distributions to the distribution of probe sets with unknown localization as follows. We assume the distribution of membrane-associated and secreted/cytoplasmic ratios for the unknown set will be approximated by a linear combination of the membrane-associated and secreted/cytoplasmic ratio distributions for the known membrane-associated and secreted and known cytoplasmic distributions, as shown in Equation 2.

\[
f_{unknown} = αf_{MS} + βf_{CYT} \tag{2}\]

To estimate the contributions of the two known distributions, we find \(α\) and \(β\) that minimize the sum of the squared errors between these two quantities as shown in Equation 3.

\[
\min_{α,β} \sum [f_{unknown} - (αf_{MS} + βf_{CYT})]^2 \tag{3}\]

For this calculation, we use discretized data (bins of width 0.01) and scale the original membrane-associated and secreted and cytoplasmic distributions to a maximum of one.

Sensitivity is defined as TP/(TP+FP), specificity is defined as TN/(TN+FN), and positive predictive value is defined as TP/(TP+FP), where TP (true positives) are the number of membrane-associated and secreted genes that are labeled correctly, FN (false negatives) are the number of membrane-associated and secreted genes that are labeled incorrectly, TN (true negatives) are the number of cytoplasmic genes that are labeled correctly, FP (false positives) are the number of cytoplasmic genes that are labeled incorrectly.

Sensitivity is a measure of the portion of membrane-associated and secreted genes we can detect, specificity is a measure of the portion of cytoplasmic genes we can detect, and positive predictive value is a measure of how many predicted membrane-associated and secreted genes are truly membrane-bound or secreted.

4 Web address: www.affymetrix.com/analysis/.
RESULTS

RNA Fractionation and Verification. The fractionation of polysomes by sucrose density gradient centrifugation was first described by Mechler (4), and it was based on the observation that genes encoding proteins that are membrane-associated or secreted are translated by ribosomes bound to the endoplasmic reticulum (membrane bound polysomes), whereas genes encoding proteins that are cytosolic are translated by ribosomes free in the cytosol (free polysomes). Membrane-bound polysomes, being less dense, rise to the top of the gradient, whereas free polysomes remain near the bottom of the gradient.

Here, the method was used to separate intact polysomes prepared from the MCF-7 breast cancer cell line. In a typical fractionation, the separation results in two distinct peaks of A_{260 nm}, with the lower peak representing free polysomes and the upper peak containing the less dense membrane-bound polysomes. To prepare sufficient RNA for Affymetrix hybridizations, it was necessary to fractionate polysomes from 3 x 10^8 cells; the results of this procedure are shown in Fig. 1. Fractions from each peak were pooled, and the fractions in the peak nearest the bottom (2 to 15) of the gradient are designated cytoplasmic, whereas fractions in the peak nearest the top of the gradient (20 though 26) are designated membrane and secreted. Sucrose fractions with near-baseline absorption (16 though 19) in between the cytoplasmic and membrane-associated and secreted pools were saved as negative controls. The peak at the surface of the gradient (the top 1.5 mL fraction) was discarded.

To confirm that the membrane-associated and secreted and cytoplasmic pools were enriched for membrane-associated and secreted-associated and cytoplasmic-associated mRNA, respectively, real-time quantitative reverse-transcriptase PCR was done with two primer pairs expected to amplify coding sequences specific for each population. We reverse transcribed 1 μg of total RNA each from the membrane-associated and secreted and cytoplasmic pools and labeled the resulting cDNA in three separate reactions for each pool. JAM1 is primarily cell-surface associated, whereas GAPDH is a protein found free in the cytoplasm. Because of their different biological sequestering, we expected JAM1 to be more highly represented in the membrane-bound polysome RNA, whereas the opposite will be true for GAPDH. To confirm the physical separation of these two RNAs, the membrane-associated and secreted/cytoplasmic expression ratio was calculated (see Table 1) by taking the ratios of the averages from the triplicates. As seen in Table 1, the membrane-associated and secreted/cytoplasmic expression ratio is about 1,000-fold greater for JAM1 than for GAPDH, demonstrating a marked enrichment in the membrane-associated and secreted pool for JAM1.

The RNA pools were then labeled and hybridized to Affymetrix U133A microarrays. Membrane-associated and secreted expression and cytoplasmic expression are the values returned by the robust multiair average calculation of expression measured on the Affymetrix array hybridized to membrane-associated and secreted and cytoplasmic RNA, respectively, and were calculated for each microarray element by averaging the expression value across the appropriate triplicate (supplementary data). The membrane-associated and secreted/cytoplasmic ratio for GAPDH (AFFX-HUMGAPDH/M33197_M_at) and JAM1 (221664_s_at) was then calculated, as shown in Table 1. As expected, the membrane-associated and secreted pool shows an enrichment for JAM1 as compared with GAPDH, whereas the cytoplasmic pool shows an enrichment for GAPDH. All microarray data are available at the Gene Expression Omnibus (14) as accession number GSE1400.

Reference Set Construction. Because the distribution of membrane-associated and secreted/cytoplasmic ratios for either class is not known a priori, it was necessary to train a classifier with a reference set of genes with known subcellular localization. Of all 22,283 elements on the Affymetrix U133A array, subcellular location annotation, as described in Materials and Methods, was available for 9,851 elements. Unambiguous membrane-associated and secreted annotation was found for 3,188 of these, whereas unambiguous cytoplasmic annotation was found for 798 elements. These elements with unambiguous annotation represent the reference set.

Expression Threshold Calculation. It is likely that only a subset of the elements on the U133A microarray will be expressed in MCF-7 cells at a level great enough for meaningful measurement. To determine that level, we evaluated our ability to distinguish known membrane-associated and secreted genes from known cytosolic genes in the reference set at various total expression (E_T) levels, where E_T = membrane-associated and secreted expression + cytoplasmic expression, where membrane-associated and secreted and cytoplasmic expression are the average exponentiated expression values for the membrane-associated and secreted and cytoplasmic microarrays, respectively. A 10-fold cross validation was done at increasing threshold levels of E_T, including only training set members with an E_T value ≥ threshold. Briefly, for each E_T level, the data were randomly partitioned into 10 groups, 9 of which were used as a “training” set, and the remaining group was designated as a “testing” set. At each E_T level, the membrane-associated and secreted/cytoplasmic ratio threshold was calculated (as described in Materials and Methods) for the training set at that E_T level. The positive predictive value, sensitivity, and specificity were calculated by examining the performance of predicting the testing set for that E_T level, and averages over the 10 groups were recorded. The results of these calculations are shown in Fig. 2. As shown in Fig. 2A, the performance of prediction for E_T thresholds ranging from 22,283 (100% of the microarray elements) to 1,106 (4.9% of the microarray elements) was examined. The E_T level that corresponded to the highest sensitivity without a significant drop in positive predictive value or specificity was 738. At this level only 24.6% of probe sets with the highest E_T are included, resulting in a.

<table>
<thead>
<tr>
<th>Target</th>
<th>MS/CYT ratio, as measured by reverse transcriptase-PCR</th>
<th>MS/CYT ratio, as measured by Affymetrix U133A microarray</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>0.00064</td>
<td>0.986</td>
</tr>
<tr>
<td>JAM1</td>
<td>0.387</td>
<td>1.173</td>
</tr>
</tbody>
</table>

Abbreviation: MS/CYT, membrane-associated and secreted/cytoplasmic.

Fig. 1. RNA content of fractions taken from the sucrose gradient. Vertical axis shows the A_{260 nm}, and the horizontal axis gives the fraction number from the bottom of the gradient.
The final dataset of 5,483 probe sets that pass this threshold filtering. At this ET level, our membrane-associated and secreted prior probability estimate is 7.2%, with a corresponding cytoplasmic prior probability of 92.8%. Of those probe sets above this ET, 538 have unambiguous membrane-associated and secreted annotation and 305 have unambiguous cytoplasmic annotation. Additionally, at this level, our 10-fold cross-validation yields a 97.5% positive predictive value with 80.7% sensitivity and 96.9% specificity.

Membrane-Associated and Secreted/Cytoplasmic Ratio Threshold Calculation. All of the 843 probe sets in the reference set (with an ET above the threshold of 723) were used to determine the membrane-associated and secreted/cytoplasmic ratio that corresponds to the maximum posterior probability of belonging to the membrane-associated and secreted class. The distribution of membrane-associated and secreted/cytoplasmic ratios for genes with known localizations was examined (Fig. 3). It is interesting to note that the cytoplasmic genes show a discrete peak, whereas the membrane-associated and secreted genes show a bimodal distribution with a smaller peak that associates with the cytoplasmic genes. The membrane-associated and secreted/cytoplasmic ratio of 1.08 was calculated as giving the maximum posterior probability. Note that above this level, the majority of known cytoplasmic genes are excluded (only 3.2% are above this level), and a sizeable fraction of the known membrane-associated and secreted genes (22%) show a lower membrane-associated and secreted/cytoplasmic ratio. Thus, genes with a ratio below 1.08 cannot be designated with certainty as either membrane-associated and secreted or cytoplasmic.

The distribution of membrane-associated and secreted/cytoplasmic ratios for the remaining probe sets (genes of unknown cellular localization) is plotted in Fig. 4. Of these, 755 probe sets fall above the expression threshold and above the membrane-associated and secreted/cytoplasmic ratio of 1.08. These 755 probe sets are labeled as “predicted membrane-associated and secreted.” The remaining 3,885 probe sets found above the expression threshold and below the membrane-associated and secreted/cytoplasmic ratio of 1.08 are labeled as “indeterminate,” because we expect a mixture of cytoplasmic and membrane-associated and secreted genes in this range of membrane-associated and secreted/cytoplasmic ratios. Of the predicted membrane-associated and secreted probe sets, 323 were found to have a tentative subcellular annotation but did not meet the criteria previously established for the reference set. The remaining 432 probe sets have no subcellular annotation. A similar percentage of indeterminate probe sets were found to have some tentative subcellular annotation (1516 of 3885).

The Swiss-Prot annotations were searched for terms that might
indicate a tentative assignment to a cellular fraction (e.g., “membrane by similarity” or “nuclear”). Table 2 summarizes the tentative localization annotations for the predicted membrane-associated and secreted and indeterminate groups. Seventy percent (214 of 323) of the predicted membrane-associated and secreted probe sets with tentative annotations indicate a membrane-associated and secreted subcellular location. The binomial probability (with the prior probability of membrane-associated and secreted class membership as calculated in Statistical Calculations) of obtaining this number of membrane-associated and secreted probe sets by chance is very low \( P < 0.005 \), indicating that the probe set population with membrane-associated and secreted/protoplasmic ratios \( \geq 1.08 \) is significantly enriched for membrane-associated and secreted genes. Less than 2% (6 of 323) of the predicted membrane-associated and secreted probe sets with tentative annotation are thought to be cytoplasmic. The remaining probe sets have either conflicting annotation or are thought to be localized to the nucleus, the endoplasmic reticulum, mitochondria, or other intracellular locations. Biochemical process annotation was available for 224 of these 323 probe sets in Gene Ontology (15). Over half of these seem to be involved in metabolism, whereas one third are involved in cell growth. Almost 25% of the predicted membrane-associated and secreted class are involved in cell communication. (Although these annotations seem to comprise a greater number than the actual number of annotated probe sets, Gene Ontology is organized in a way such that multiple annotations can correspond to a single probe set.)

In contrast, 7.5% (113 of 1516) of the indeterminate probe sets with tentative annotation indicate a membrane-associated and secreted localization. Although only 12.5% (189 of 1516) of these are thought to be cytoplasmic, a significant fraction of the probe sets with conflicting annotation indicate a possible cytoplasmic localization. Interestingly, >60% of the indeterminate probe sets contain nuclear or mitochondrial annotation.

Analysis of a Gene Expression Study for Membrane-Associated and Secreted Gene Content. The MCF-7 membrane-associated and secreted gene dataset was used to filter a differential gene expression study in breast cancer, which compared tumors with good versus poor 5-year outcome (5). We asked whether the membrane-associated and secreted localization provided by our study might give additional insight into the interpretation of the results and facilitate the selection of target genes for additional evaluation.

In the van’t Veer et al. (5) study, RNA from 98 primary breast tumors was hybridized to cDNA microarrays, and the resultant analysis led to a 231-gene expression profile associated with poor prognosis. The original study was preformed on cDNA glass slide microarrays; therefore, we needed to find which elements of the Affymetrix U133A microarray corresponded to the 231 genes from the original study. It was possible to map 166 of these 231 genes to 269 probe sets on the Affymetrix microarray. Of these 269 probe sets, 20 were found in our predicted membrane-associated and secreted database representing 15 unique genes (see Table 3); an additional 52 were found in our training set of previously known membrane-associated and secreted genes. Of the genes not in the training set, almost half (7 of 15) had no subcellular location annotation in Gene Ontology or Swiss-Prot, although one had a published characterization.

Of the 9 genes with functional annotation, 5 are involved in metabolism, along with one each involved in signal transduction, cell-cycle regulation, proteolysis, and calcium binding. It is interesting to note that of the genes without functional annotation, HCCR1 is a putative proto-oncogene, fucosyltransferase 8 is thought to contribute to malignancy, “G protein-coupled receptor 126” contains a “protein tyrosine phosphatase-like protein” domain, and “hypothetical protein FLJ22341” contains a rhomboid domain, thought to regulate epidermal growth factor receptor expression. Any of these proteins, the up-regulation of which is associated with poor prognosis in breast cancer, merit additional investigation as potential treatment targets.

DISCUSSION

We describe here a novel set of membrane-associated and secreted genes expressed in MCF-7 cells. We are able to annotate 755 probe sets as membrane-associated or secreted, 432 of which had no previous subcellular location annotation. Two levels of validation strengthen our location predictions. First, we did 10-fold cross validation on the set of genes with annotated localization, which is a robust method for estimating performance on future datasets with similar characteristics. On the basis of the results of the 10-fold cross validation, it is likely that a great number of the predicted membrane-associated and secreted genes will have membrane-associated and secreted localization. This is reflected by the average 97% positive predictive value observed in the 10-fold cross validation. Second, we examined the tentative annotations of genes in the set that were not used in the cross validation test and for which we predicted subcellular localization. Many of these have some tentative annotation, which we do not consider definitive. Nevertheless, our membrane-associated and secreted predictions coincide with these tentative annotations 70% of the time.

Here we describe a general method of applying density gradient fractionation of RNA to the Affymetrix platform, including a robust statistical analysis. Furthermore, we have described an approach that can easily be modified for other tissues or states for comparative studies.

To minimize technical variability, hybridization data were collected in triplicate, with three independent labeling experiments on RNA collected from one fractionation experiment. It was not possible to compare the results obtained from multiple fractionations of different cell cultures because of the prohibitive cost of processing these large volumes of cells and of Affymetrix hybridization. Thus, the results shown here represent a “snapshot” of a cell line at a single point in time; it is possible that the representation of some genes, and even their membrane-associated and secreted/cytoplasmic distribution, will vary with different culture conditions. Indeed, this approach might be used to investigate global changes in subcellular distribution of proteins under various biological conditions, which to our knowledge has not been addressed previously.

Our Bayesian analysis may be over- or underestimating membrane-associated and secreted localization because of some violations of the equation assumptions. The localization of different genes are not entirely independent observations. For instance, there are clearly genes that colocalize because of genetic interactions. In addition, we
make the assumption that these two classes are mutually exclusive, which may not be true for a small fraction of genes. The robust multiaarray average algorithm might be a different source of underestimation for membrane-associated and secreted prediction, as it uses quantile normalization and might be overcorrecting for underrepresented membrane-associated and secreted/cytoplasmic threshold. It is unclear if this is because of a real biological process (some of those membrane-associated and secreted/cytoplasmic genes are not membrane-associated and secreted genes). Alternative microarray processing algorithms may yield additional predicted membrane-associated and secreted genes. It is possible that alternative microarray processing algorithms may yield additional predicted membrane-associated and secreted genes. Alternative statistical methods may be useful for additional analysis and confirmation of our results.

There are a significant number of genes with unambiguous membrane-associated and secreted annotation that fall below our membrane-associated and secreted/cytoplasmic threshold. It is unclear if this is because of a real biological process (some of those membrane-associated and secreted genes are not membrane-associated and secreted localized in MCF-7 cells, for instance) or a processing artifact. Additional experimental analysis is needed to elucidate the mechanism in action. Additional study is also needed to determine whether the protein localization we discovered for MCF-7 cells holds true when analyzing other breast cancer cells.

ACKNOWLEDGMENTS

The authors wish to acknowledge the helpful equipment support of Dr. Alexander Mankin from University of Illinois at Chicago Pharmaceutical Biotechnology and the technical assistance of Mr. Doron Galili.

REFERENCES